Using Local Therapy to Control Noninfectious Uveitis
Lazha Ahmed Talat Sharief, MPH, MSc(Ophth) - London, United Kingdom
Sue Lightman, PhD, FRCOphth - London, United Kingdom
Oren Tomkins-Netzer, MD, PhD - London, United Kingdom, and Haifa, Israel

Treating uveitis aims to prevent the development of ocular structural changes related to intraocular inflammation that otherwise could lead to vision loss. Inflammation control is achieved with immunosuppressive drugs, primarily corticosteroids, and for many years has relied on these, particularly in cases with concomitant systemic diseases or bilateral uveitis. Although these drugs are effective in controlling the inflammation, many patients do not have systemic involvement and are not keen to undertake systemic treatment. Direct access to the intraocular space means the eye is an ideal organ for local therapy, achieving high drug concentration on target.

**Direct access to the intraocular space means the eye is an ideal organ for local therapy, achieving high drug concentration on target.**

The Multicentre Uveitis Steroid Treatment trial is a multinational trial that was established as a prospective interventional study to compare local and systemic treatment for NIU. It examined the effect of systemic immunosuppression treatment on long-term control of NIU with long-acting local therapy in the form of a surgically inserted fluocinolone acetonide implant (Retisert; Bausch & Lomb, Bridgewater, NJ), reported to maintain a constant intravitreal level of corticosteroids for up to 30 months. The interventional trial ran for 24 months, with 255 patients (479 eyes with uveitis) randomized to either systemic immunosuppression or a fluocinolone implant who were followed up for an additional 5 years as part of an observational study. The primary results demonstrated that at 24 months, the implant resulted in comparable visual improvement to systemic immunosuppression with greater inflammatory control and macular edema (ME) resolving in two thirds of eyes from both groups. Interestingly, more than 60% of eyes treated systemically still required at least 1 supplemental local steroid injection. These trends remained stable throughout the next 30 months and were only lost at 7 years of follow-up, when eyes treated systemically showed a greater visual benefit of 7.2 letters. Eyes receiving the implants had 90% of phakic eyes requiring cataract surgery and 45% undergoing surgery to control raised intraocular pressure. However, the visual function remained comparable, and many patients were disease free for many years without the need for additional treatment. The injectable fluocinolone inserts (Iluvien; Alimera Sciences, Aldershot, UK) avoid the need for surgery, provide long-term immunosuppression, and possibly accompany a smaller risk of systemic side effects developing related to systemic corticosteroids or long-term use of steroid-sparing agents. The dexamethasone implant (Ozurdex; Allergan, Irvine, CA) has been licensed for the treatment of uveitis, offering a delay-release treatment option that may have a reduced risk of ocular complications compared with other local corticosteroids. The HURON trial demonstrated that after a single implantation, treated eyes were more likely to achieve inflammatory control and improved vision than untreated eyes. In both adults and children, the effect lasts for several months and then can be repeated as needed. The risk of cataract and glaucoma developing is relatively low, with most patients not requiring surgical intervention. The addition of local treatment as an adjunctive to systemic immunosuppression in young patients can help to reduce their risk of systemic side effects developing related to systemic corticosteroids or long-term use of steroid-sparing agents. With an extended duration, these patients could experience long periods with good inflammatory control and no additional treatment. To clarify the place of each of these agents as treatment options for NIU, the
Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema trial is an ongoing multicenter, randomized trial designed to compare the relative efficacy of periocular triamcinolone injection, (Kenalog; Bristol-Myers Squibb Co., Princeton, NJ), IVTA injection, and the intravitreal dexamethasone implant. The trial will include 267 patients with uveitic ME randomized to 1 of the 3 treatment arms and will compare the percent change in central retinal thickness from baseline to the 8-week visit, duration of effect, change in visual acuity, and the need for additional injections by 24 weeks for each of these treatment options.

Intravitreal methotrexate injections (400 µg/0.1 ml) may be considered an alternative in refractory cases. Although few studies have examined this treatment option, it seems to offer a duration of effect of up to 4 months and a reduced risk of ocular hypertension.11 It has been reported that some of the treated eyes may even achieve a longer remission, suggesting it may be a suitable option for glaucomatous patients or those with a history of steroid-induced ocular hypertension.

The rationale for using intravitreal anti-VEGF drugs for treating NIU relates to blocking VEGF, restricting the induction of proinflammatory cytokines, and reversing increased vascular permeability. Anti-vascular endothelial growth factor is considered as treatment option mainly for refractory inflammatory ME, neovascularization, and choroidal neovascular membrane. Small series studies suggest that using anti-VEGFs in eyes with uveitic ME can lead to a reduction in ME and improved vision; however, the current level of evidence is regarded as low quality, lacking a conclusive comparison with other options, such as intravitreal corticosteroids. The mechanism of action of these drugs limits their effect as anti-inflammatory agents and possibly restricts their use only to selective cases of refractory ME in otherwise nonactive uveitis. The multicenter Macular Edema Ramibuzumab v. Intravitreal Anti-inflammatory Therapy trial is an ongoing randomized prospective study comparing the relative efficacy and safety over 6 months of intravitreal methotrexate, ranibizumab, and the dexamethasone implant for persistent uveitic ME. The trial includes 240 patients randomized to the 3 treatment arms and will compare the percent change in central retinal thickness from the baseline to the 12-week visit, improvement in vision, and adverse events.

Anti-tumor necrosis factor drugs are taking on a prominent role in controlling uveitis, with adalimumab recently approved in the United States and Europe for treatment of NIU not responding to corticosteroids and at least 1 additional immunosuppression agent. The intravitreal use of these drugs has been the focus of several studies with conflicting results. Although small prospective studies have demonstrated improved visual acuity and inflammatory control for both intravitreal infliximab and adalimumab, there is a reported increased risk of persistent ME and an intraretinal immunogenic reaction.16 The efficacy of intravitreal sirolimus was examined in the Sirolimus Study Assessing Double-Masked Uveitis Treatment study17 and found that those receiving an intravitreal dose of 440 µg demonstrated a significant reduction in vitreous haze and ocular inflammation and maintained good visual outcome, and 77% of patients were able to taper off systemic corticosteroids.

Local therapy, although not without significant ocular complications—primarily cataract progression and raised intraocular pressure related to use of corticosteroids—nevertheless can provide lasting good control of intraocular inflammation and can stabilize vision. The need to repeat these invasive procedures remains a limiting factor, particularly among young patients. However, long-lasting agents, office-based injection procedures, and improved patient response make these an important tool for long-term control and a disease-free state in such young patients with chronic disease.

References


**Footnotes and Financial Disclosures**

Financial Disclosure(s): The author(s) have made the following disclosure(s): S.L.: Consultant Allergan, GSK, 4Sight Bayer, AbbVie, Paraxcel; Advisory board — Allergan, Bayer, AbbVie, Santen, GSK.

O.T.-N.: Consultant — AbbVie.

Correspondence: Oren Tomkins-Netzer, MD, PhD, University College London, City Road, London EC1V 2PD, United Kingdom. E-mail: o.tomkins-netzer@ucl.ac.uk.